Literature DB >> 34045551

Single tryptophan Y160W mutant of homooligomeric E. coli purine nucleoside phosphorylase implies that dimers forming the hexamer are functionally not equivalent.

Marta Narczyk1, Łukasz Mioduszewski1,2, Aleksandra Oksiejuk1,3, Maria Winiewska-Szajewska1,4, Beata Wielgus-Kutrowska1, Adrian Gojdź5, Joanna Cieśla5, Agnieszka Bzowska6.   

Abstract

E. coli purine nucleoside phosphorylase is a homohexamer, which structure, in the apo form, can be described as a trimer of dimers. Earlier studies suggested that ligand binding and kinetic properties are well described by two binding constants and two sets of kinetic constants. However, most of the crystal structures of this enzyme complexes with ligands do not hold the three-fold symmetry, but only two-fold symmetry, as one of the three dimers is different (both active sites in the open conformation) from the other two (one active site in the open and one in the closed conformation). Our recent detailed studies conducted over broad ligand concentration range suggest that protein-ligand complex formation in solution actually deviates from the two-binding-site model. To reveal the details of interactions present in the hexameric molecule we have engineered a single tryptophan Y160W mutant, responding with substantial intrinsic fluorescence change upon ligand binding. By observing various physical properties of the protein and its various complexes with substrate and substrate analogues we have shown that indeed three-binding-site model is necessary to properly describe binding of ligands by both the wild type enzyme and the Y160W mutant. Thus we have pointed out that a symmetrical dimer with both active sites in the open conformation is not forced to adopt this conformation by interactions in the crystal, but most probably the dimers forming the hexamer in solution are not equivalent as well. This, in turn, implies that an allosteric cooperation occurs not only within a dimer, but also among all three dimers forming a hexameric molecule.

Entities:  

Year:  2021        PMID: 34045551     DOI: 10.1038/s41598-021-90472-4

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  24 in total

Review 1.  Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implications.

Authors:  Sebastian E Sattui; Angelo L Gaffo
Journal:  Ther Adv Musculoskelet Dis       Date:  2016-05-02       Impact factor: 5.346

2.  Efficient Fludarabine-Activating PNP From Archaea as a Guidance for Redesign the Active Site of E. Coli PNP.

Authors:  Giovanna Cacciapuoti; Maria Libera Bagarolo; Elisa Martino; Bernardina Scafuri; Anna Marabotti; Marina Porcelli
Journal:  J Cell Biochem       Date:  2015-10-18       Impact factor: 4.429

Review 3.  Structural analyses reveal two distinct families of nucleoside phosphorylases.

Authors:  Matthew J Pugmire; Steven E Ealick
Journal:  Biochem J       Date:  2002-01-01       Impact factor: 3.857

4.  Purine-nucleoside phosphorylase from Salmonella typhimurium and Escherichia coli. Initial velocity kinetics, ligand banding, and reaction mechanism.

Authors:  K F Jensen
Journal:  Eur J Biochem       Date:  1976-01-15

5.  6-Methylpurine derived sugar modified nucleosides: Synthesis and in vivo antitumor activity in D54 tumor expressing M64V-Escherichia coli purine nucleoside phosphorylase.

Authors:  Abdalla E A Hassan; Reham A I Abou-Elkhair; William B Parker; Paula W Allan; John A Secrist
Journal:  Eur J Med Chem       Date:  2015-12-17       Impact factor: 6.514

6.  Open and closed conformation of the E. coli purine nucleoside phosphorylase active center and implications for the catalytic mechanism.

Authors:  Gertraud Koellner; Agnieszka Bzowska; Beata Wielgus-Kutrowska; Marija Luić; Thomas Steiner; Wolfram Saenger; Janusz Stepiński
Journal:  J Mol Biol       Date:  2002-01-18       Impact factor: 5.469

7.  The crystal structure of Escherichia coli purine nucleoside phosphorylase: a comparison with the human enzyme reveals a conserved topology.

Authors:  C Mao; W J Cook; M Zhou; G W Koszalka; T A Krenitsky; S E Ealick
Journal:  Structure       Date:  1997-10-15       Impact factor: 5.006

Review 8.  Purine nucleoside phosphorylases: properties, functions, and clinical aspects.

Authors:  A Bzowska; E Kulikowska; D Shugar
Journal:  Pharmacol Ther       Date:  2000-12       Impact factor: 12.310

9.  hTERT-targeted E. coli purine nucleoside phosphorylase gene/6-methylpurine deoxyribose therapy for pancreatic cancer.

Authors:  Jia-hua Zhou; Bo Tang; Xun-liang Liu; Dao-wei He; De-tong Yang
Journal:  Chin Med J (Engl)       Date:  2007-08-05       Impact factor: 2.628

10.  Designer gene therapy using an Escherichia coli purine nucleoside phosphorylase/prodrug system.

Authors:  Eric M Bennett; Ruchi Anand; Paula W Allan; Abdalla E A Hassan; Jeong S Hong; Dana N Levasseur; David T McPherson; William B Parker; John A Secrist; Eric J Sorscher; Tim M Townes; William R Waud; Steven E Ealick
Journal:  Chem Biol       Date:  2003-12
View more
  1 in total

1.  Thermodynamic Studies of Interactions between Sertraline Hydrochloride and Randomly Methylated β-Cyclodextrin Molecules Supported by Circular Dichroism Spectroscopy and Molecular Docking Results.

Authors:  Sylwia Belica-Pacha; Mateusz Daśko; Vyacheslav Buko; Ilya Zavodnik; Katarzyna Miłowska; Maria Bryszewska
Journal:  Int J Mol Sci       Date:  2021-11-16       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.